DiaMedica Therapeutics Inc. Common Stock

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DMAC and other ETFs, options, and stocks.

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).

CEO

Rick John Pauls

CEORick John Pauls

Employees

Employees28

Headquarters

Minneapolis, Minnesota

HeadquartersMinneapolis, Minnesota

Founded

2000

Founded2000

Employees

Employees28

DMAC Key Statistics

Market cap

241.90M

Market cap241.90M

Price-Earnings ratio

-7.23

Price-Earnings ratio-7.23

Dividend yield

—

Dividend yield—

Average volume

411.10K

Average volume411.10K

High today

$4.94

High today$4.94

Low today

$4.41

Low today$4.41

Open price

$4.82

Open price$4.82

Volume

389.86K

Volume389.86K

52 Week high

$6.82

52 Week high$6.82

52 Week low

$3.19

52 Week low$3.19

DMAC News

Seeking Alpha 3d

DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer

Healthcare DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer Aug. 06, 2025 8:48 AM ET DiaMedica Therapeutics Inc. (DMAC) Stock By: Akanksha Kh...

People also own

Based on the portfolios of people who own DMAC. This list is generated using Robinhood data, and it’s not a recommendation.